AzTrials
AzTrials

Swallowing DisorderNCT03590457

The Impact of High-Flow Nasal Cannula on Swallow Function

A study testing Airvo 2; High-Flow nasal cannula system in people with Swallowing Disorder and Respiratory Insufficiency, run by Rush University Medical Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background: High-flow nasal cannula (HFNC) is a non-invasive heated and humidified oxygen delivery device that is capable of delivering high-flow rates. It is a relatively new modality that has been introduced as an alternative to conventional oxygen therapy. Read more about this study

Who is it for?
Ages 21 years and olderHealthy volunteers can take part
What is being tested?
Airvo 2; High-Flow nasal cannula system
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
18 participants
Where
1 siteUnited States
Study dates
22 Jun 2018to 1 Dec 2019
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • 21 years of age or older
  • No cognitive impairments

Who cannot join

  • Less than 21 years old
  • History of swallow dysphagia
  • History of disease/condition that may cause dysphagia
  • Use of medications that may alter swallow function
  • Nasal obstruction
  • Presence of tracheostomy tube

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Rush University Medical Center

    Chicago, Illinois, 60187

Other trials in United States

About this study

Background: High-flow nasal cannula (HFNC) is a non-invasive heated and humidified oxygen delivery device that is capable of delivering high-flow rates. It is a relatively new modality that has been introduced as an alternative to conventional oxygen therapy. The clinical value of the use of HFNC is not limited to its ventilation and oxygenation effects, it enables the patient to talk and is purported to permit oral feeding during oxygen therapy despite the limited evidence regarding its impact on swallow function. This study will determine the impact of different flow rates of a high-flow nasal cannula on spontaneous swallowing frequency at rest and swallowing effort and timing while swallowing. Methods: This is a prospective study designed to measure swallowing frequency and swallowing effort in fifty healthy adult volunteers. Participants will receive three levels of HFNC flow rates (30, 45, and 60 L/min) through nasal prongs. The study participants will be asked to swallow measured amounts of water and applesauce and subjected to each flow rate for 15 minutes. Swallowing effort measurement through surface electromyography (sEMG) will be recorded at baseline and the three levels of HFNC flow rates interventions.

Read the detailed description

High-flow nasal cannula (HFNC) is a non-invasive heated and humidified oxygen delivery device that is capable of delivering up to 60 L/min of flow. It is a relatively new modality that has been introduced as an alternative to conventional oxygen therapy in patients with chronic obstructive pulmonary disease (COPD) respiratory failure, obstructive sleep apnea (OSA)6, post-extubation, and status asthmaticus The humidified gas preserves mucociliary function that prevents secretion retention and enhances patient's comfort. This feature allows prolonged use of HFNC in clinical sittings of up to 30 days

In addition to its ability to provide adequate humidification levels, HFNC has various respiratory physiological effects. These physiological effects include: alveolar recruitment, dead space washout, and decreased airway resistance. The clinical value of the use of HFNC is not limited to its ventilation and oxygenation effects, it enables the patient to talk and is purported to permit oral feeding during oxygen therapy.

Currently, despite the fact that patients are often permitted to eat while receiving HFNC therapy, there is insufficient evidence regarding the impact of HFNC on swallow function. The uncertainty of the effect of this oxygen delivery device on swallow function arises not only from the limited number of studies, but also the contradictory results. For example, Sanuki et al. reported that increasing the flow rates of the HFNC resulted in enhanced swallow function by reducing reflex latency. Based on their findings, the researchers suggested that the use of HFNC should not affect the decision to start or resume feeding. Similarly, Lader et al. proposed that the use of high-flow nasal cannula should not delay oral alimentation. On the contrary, Ferrara et al. conducted a study in neonates and concluded that providing feeding while using Nasal Continuous Positive Airway Pressure (nCPAP) increased the risk of aspiration. These opposing outcomes support the need for further studies to obtain more definitive evidence.

Methods:

Spontaneous Swallowing Frequency:

Spontaneous swallowing is an airway protection reflex and the measurement of its frequency is considered to be a sensitive indicator of swallow function. This index can sensitively identify dysphagia and other swallowing-related disorders. Furthermore, the reduction in this index is associated with increased level of secretions and chest infections. One modality used to measure swallowing frequency is surface electromyography (sEMG), which records electric activity during swallow via an electrode placed on the skin under the chin. This non-invasive technology has been used for more than 20 years to record various aspects of swallowing physiology. In this study, sEMG will be used because of its feasibility, accuracy, and ability to detect a swallow.

Swallowing Effort and Timing:

Swallowing effort via submental sEMG provides an objective measurement of lingual and sub-mental muscle activity during the act of swallowing. Measurements include muscle contraction amplitude and contraction timing/speed. Clinically, swallowing effort parameters have been used to document normative values in healthy individuals, as well as to document the effects of a disease on swallowing. Prior research has shown that both amplitude and timing are influenced by multiple factors including the volume and viscosity of the item (or bolus) being swallowed, and the age and gender of the person swallowing. However no study has investigated the effects of HFNC on either swallowing effort parameter.

The primary aim of this research is to determine the impact of different flow rates of a high-flow nasal cannula on spontaneous swallowing frequency at rest and swallowing effort and timing while swallowing.

This is a prospective study designed to measure swallowing frequency and swallowing effort in fifty healthy adult volunteers (25 participants will be between 21 and 49 years old; and the other 25 above 50 years old). To recruit volunteer participants, an email will be sent via university internal email system to the faculty, students and employees in the departments of Respiratory Care and Speech Language Pathology. Snowball sampling (non-probability sampling) will also be utilized to recruit individuals outside of those departments. No compensation is offered to the participants. Enrolled participants are sub-categorized into two different age groups to determine if there are any swallowing differences between the different age groups. Inclusion criteria include individuals who are older than 21 years of age and have no cognitive impairment. Exclusion criteria include individuals who are less than 21 years of age, have a history of dysphagia or disease/condition that may cause dysphagia, current use of medications that alter swallowing function, nasal obstruction, and the presence of a tracheostomy tube.

Upon meeting inclusion criteria, informed consent explaining the procedure and potential harm will be obtained and a copy will be given to the subject. Then, a unique identification code number will be assigned to protect the subject's identity.

HFNC:

The AIRVO 2 high-flow nasal cannula system (Fisher and Paykel Healthcare Limited, Panmure, Auckland, New Zealand) will be used. Nasal prongs sizes are chosen as per manufacturer recommendations. Participants will receive three levels of HFNC flow rates (30, 45, and 60 L/min) through nasal prongs. If a small-size nasal prong is used, the participant will receive 30, 45, and 50 L/min flow rates instead of 30, 45, and 60 L/min, as manufacturer recommendations state the maximum liter flow for a small-size nasal prong is 50 L/min. Oxygen concentration will be set at 21% and a temperature of 37 °C. First, individuals will be placed on the sEMG monitor. Following the application of the sEMG, each participant will sit quietly for 10 minutes, before being attached to the HFNC, so a baseline swallow frequency can be established. After the baseline swallow frequency is established, each participant will be asked to swallow 8 boluses: 2 trials of water at 2 volumes (5 and 10 mL) and 2 trials of applesauce at 2 volumes (5 and 10 mL). Participants will rest for 15 seconds after completing each swallow. This procedure will establish the participant's baseline swallowing effort measurements. Once these swallows have been completed, the participant will be placed on the HFNC. Each participant will be placed on three different flow rates (30, 45, and 60 L/min or 30, 45, and 50 L/min) in random order. The random order will be generated by an online random number tool (https://www.randomizer.org). The study participant will be subjected to each flow rate for 15 minutes. During the first 10 minutes, swallow frequency will be recorded. After 10 minutes at the given flow, the participant will complete the 8 aforementioned swallows. After completing all of the swallowing trials, the participant will be removed from the HFNC for a period of 10 minutes. This process will be repeated for all three flowrates for a total of 32 boluses swallowed.

Swallowing Frequency:

Swallowing frequency is analyzed by sEMG signals recorded on the KayPentax Digital Swallow Workstation™ with integrated digital swallowing signals lab (DSW™, Model 7120, New Jersey). A three-sensor sEMG electrode (Uni-Patch™, Disk #7500, Covidien Corporation, Tyco Healthcare, Wabasha, MN) will be placed on the anterior neck skin under the chin, over the submental muscles above the hyoid bone. Each patch will include two recording electrodes and a third ground electrode. Spontaneous swallowing frequency is calculated as the number of swallows per minute (SPM) for 10 minutes on room air and then for each HFNC intervention. Swallows will be counted from the visual myographic waveform produced by the DSW.

Swallowing Effort:

Both swallowing amplitude and timing parameters will be obtained by analyzing the individual graphic waveforms produced by the DSW algorithm. Measures will be obtained for each of the 8 swallows, at each of the HFNC flow rates.

Procedures Done for Research Purpose

The use of HFNC with three levels of flow (30, 45, and 60 L/min or 30, 45, and 50 L/min [for small-size nasal prongs]).

Swallow frequency measurement through sEMG.

Swallowing effort measurement through sEMG - participants will swallow measured amounts of water and applesauce. Presentation of the different volumes and viscosities will be done in pre-determined random order.

Being tested
Airvo 2; High-Flow nasal cannula system
Medical subject headings
Deglutition Disorders, Respiratory Insufficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Airvo 2; High-Flow nasal cannula systemDevice

    Noninvasive device used to deliver humidified oxygen at high flow rates up to 60 liters per minute

Study groups in NCT03590457
Study groupRoleWhat they receive
High-Flow/SwallowOtherAll participants will be subjected to all three flows randomly. All participants will be asked swallow water and applesauce
Receives: Device: Airvo 2; High-Flow nasal cannula system

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Swallow Frequency Recorded by Surface Electromyography (sEMG)

    Number of swallows

    Measured: each swallow frequency exam took 1 minute, exams were done for each flow rate which took up to 2 hours to complete

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jul 2018
  2. Study start22 Jun 2018
  3. Primary completion1 Dec 2019
  4. Study completion1 Dec 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
18 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03590457
Sponsor's protocol ID
18012503
Status last verified
Aug 2022
First submitted
26 Jun 2018
Last updated
27 Sep 2022
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Airvo 2; High-Flow nasal cannula system in people with Swallowing Disorder and Respiratory Insufficiency, run by Rush University Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 27 Sep 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Swallow Frequency Recorded by Surface Electromyography (sEMG) (time frame: each swallow frequency exam took 1 minute, exams were done for each flow rate which took up to 2 hours to complete). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Sep 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in